IRVINE, Calif., Nov. 21, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneer in advancing Boron Neutron Capture Therapy (BNCT) for cancer treatment, today announced groundbreaking findings from its recent research, heralding a new chapter in company's pursuit of making Boron Neutron Capture Therapy (BNCT) a viable and globally accepted cancer treatment. The study focused on the development and boron delivery capabilities of Boronotyrosine (BTS), a novel borylated amino acid analogue that will redefine the cancer-fighting potential of BNCT.
IRVINE, Calif., Aug. 15, 2023 /PRNewswire/ -- TAE Life Sciences has today announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino acid analog drug for boron neutron capture therapy (BNCT). As part of this exclusive agreement, Biddle Sawyer has enlisted contract research and manufacturing organization Kinentia Biosciences to refine and streamline the drug's manufacturing process, and ultimately produce the drug in their state-of-the-art GMP facility. Kinentia Biosciences will be the exclusive manufacturer of TC220 for the US market.
MADRID and IRVINE, Calif., June 9, 2023 /PRNewswire/ -- TAE Life Sciences, a pioneering company in the field of cancer treatment, announces its participation in the 61st annual Particle Therapy Co-Operative Group (PTCOG) conference in Madrid, Spain. The event, held from June 10 – 16, 2023, will bring together leading experts, researchers, and organizations dedicated to advancing particle therapy in cancer treatment. TAE Life Sciences will be actively engaged in the conference, sharing scientific breakthroughs via oral and poster presentations, as well as co-hosting a symposium on Boron Neutron Capture Therapy (BNCT).
TAE Life Sciences Announces Partnership with HDX Corporation for Launch of Boron Neutron Capture Therapy in South Korea
FOOTHILL RANCH, Calif.--(BUSINESS WIRE)--TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 22-26, 2022.